Literature DB >> 28861594

[Corticosteroids compromise survival in glioblastoma patients after radio- and chemotherapy].

Clemens Seidel1, Rolf-Dieter Kortmann2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28861594     DOI： 10.1007/s00066-017-1201-2

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  6 in total

1.  Corticosteroids compromise survival in glioblastoma in part through their elevation of blood glucose levels.

Authors:  Rainer J Klement; Colin E Champ
Journal:  Brain       Date:  2017-03-01       Impact factor: 13.501

2.  Chemotherapy of human malignant glioma: prevention of efficacy by dexamethasone?

Authors:  M Weller; C Schmidt; W Roth; J Dichgans
Journal:  Neurology       Date:  1997-06       Impact factor: 9.910

3.  Induction of the DNA repair gene O6-methylguanine-DNA methyltransferase by dexamethasone in glioblastomas.

Authors:  Shigeo Ueda; Toshihiro Mineta; Yukiko Nakahara; Hiroaki Okamoto; Tetsuya Shiraishi; Kazuo Tabuchi
Journal:  J Neurosurg       Date:  2004-10       Impact factor: 5.115

4.  Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma.

Authors:  E T Wong; E Lok; S Gautam; K D Swanson
Journal:  Br J Cancer       Date:  2015-06-30       Impact factor: 7.640

5.  Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide.

Authors:  Minh Thi Tieu; Leif E Lovblom; Mairéad G McNamara; Warren Mason; Normand Laperriere; Barbara-Ann Millar; Cynthia Ménard; Tim-Rasmus Kiehl; Bruce A Perkins; Caroline Chung
Journal:  J Neurooncol       Date:  2015-05-27       Impact factor: 4.130

6.  Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.

Authors:  Lisa B E Shields; Brent J Shelton; Andrew J Shearer; Li Chen; David A Sun; Sarah Parsons; T David Bourne; Renato LaRocca; Aaron C Spalding
Journal:  Radiat Oncol       Date:  2015-10-31       Impact factor: 3.481
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.